Astellas Pharma Inc. (TSE: 4503) and Pfizer Inc. (NYSE: PFE) announced compelling five-year overall survival (OS) results from the open-label exten...
In this exclusive interview with BioPharma BoardRoom, Jessay Devassy, Manager, Bioprocess Applications at Ecolab Bioprocessing&...
Eli Lilly and Company announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing authorization for Kisunla (d...
Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel ther...
Synfini, Inc., the leader in AI-driven agile chemistry for better molecule discovery, announced today that it has entered a collaboration with biotechnol...
ODAC recommendation based on the positive progression-free survival and clinical benefit in the Phase 3 AQUILA study If approved, DARZALEX FASPRO® w...
FedEx becomes first global integrator to achieve CEIV Pharma certification for ground handling across its air hubs and ramps. FedEx Corp. anno...
Rani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, announced the compa...
Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaborat...
-Bayer announced that the U.S. Food and Drug Administration (FDA) has approved Jivi®, a recombinant DNA-derived, extended half-life factor VIII conce...
Brain Cancer Canada is pleased to award $68,000 for an innovative research initiative led by Dr. Aru Narendran, MD, PhD, and Dr. Patrick Sipila, PhD, at ...
FDA's approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, marking a pivotal moment in the fight against Alzheimer's disease. This is the f...
Fujirebio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the company’s Lumipulse® G pTau 217/&beta...
The Asthma and Allergy Foundation of America (AAFA) appreciates the President’s Executive Order calling attention to America’s persistent pro...
© 2025 Biopharma Boardroom. All Rights Reserved.
